Cytokinetics (CYTK) Launches MYQORZO for Obstructive HCM in Germany

AI Summary

Cytokinetics (CYTK) initiated the first commercial launch of MYQORZO (aficamten) in Germany on June 1, 2026, for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This launch follows European Commission approval received in February 2026, alongside prior approvals in the US and China. The drug's market entry is based on favorable Phase 3 SEQUOIA-HCM trial results, demonstrating statistically significant improvements in exercise capacity and quality-of-life measures compared to placebo. This launch is part of a broader strategy to expand access to MYQORZO across Europe, highlighting the drug's clinical efficacy and regulatory validation.